BeiGene, Ltd. (BGNE): Price and Financial Metrics


BeiGene, Ltd. (BGNE): $341.45

14.03 (+4.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BGNE POWR Grades


  • BGNE scores best on the Growth dimension, with a Growth rank ahead of 81.53% of US stocks.
  • The strongest trend for BGNE is in Momentum, which has been heading down over the past 31 weeks.
  • BGNE's current lowest rank is in the Momentum metric (where it is better than 9.33% of US stocks).

BGNE Stock Summary

  • BGNE's price/sales ratio is 33.43; that's higher than the P/S ratio of 93% of US stocks.
  • With a year-over-year growth in debt of 114.26%, BeiGene Ltd's debt growth rate surpasses 91.6% of about US stocks.
  • Revenue growth over the past 12 months for BeiGene Ltd comes in at 114.37%, a number that bests 94.66% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to BGNE, based on their financial statements, market capitalization, and price volatility, are TECH, ANET, G, HRL, and FLT.
  • Visit BGNE's SEC page to see the company's official filings. To visit the company's web site, go to www.beigene.com.

BGNE Valuation Summary

  • In comparison to the median Healthcare stock, BGNE's price/earnings ratio is 173.53% lower, now standing at -25.
  • BGNE's price/sales ratio has moved down 32.3 over the prior 67 months.
  • BGNE's price/earnings ratio has moved up 22.2 over the prior 67 months.

Below are key valuation metrics over time for BGNE.

Stock Date P/S P/B P/E EV/EBIT
BGNE 2020-11-17 97.4 6.0 -17.1 -16.2
BGNE 2020-05-29 31.9 4.6 -11.2 -9.7
BGNE 2019-11-11 26.6 7.4 -17.4 -15.8
BGNE 2019-09-26 17.8 5.0 -11.6 -10.3
BGNE 2019-01-22 51.3 4.1 -16.0 -14.8
BGNE 2017-03-02 150.2 7.1 -23.2 -22.5

BGNE Stock Price Chart Interactive Chart >

Price chart for BGNE

BGNE Price/Volume Stats

Current price $341.45 52-week high $388.97
Prev. close $327.42 52-week low $207.96
Day low $323.03 Volume 478,700
Day high $343.00 Avg. volume 264,556
50-day MA $334.37 Dividend yield N/A
200-day MA $313.77 Market Cap 31.54B

BeiGene, Ltd. (BGNE) Company Bio


BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands.


BGNE Latest News Stream


Event/Time News Detail
Loading, please wait...

BGNE Latest Social Stream


Loading social stream, please wait...

View Full BGNE Social Stream

Latest BGNE News From Around the Web

Below are the latest news stories about BeiGene Ltd that investors may wish to consider to help them evaluate BGNE as an investment opportunity.

BeiGene's Brukinsa Prolongs Progression-Free Survival Compared To Chemo In Untreated Blood Cancer Patients

BeiGene Ltd (NASDAQ: BGNE) announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing Brukinsa (zanubrutinib) to bendamustine and rituximab (B+R). The trial included patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose tumor did not exhibit the deletion of chromosome 17p13.1 (del[17p]). With a median follow-up of 25.8 months, Brukinsa achieved a highly statistically significant improvement in progr

Yahoo | July 30, 2021

BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company, today announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing BRUKINSA® (zanubrutinib) to bendamustine and rituximab (B+R) in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose tumor did not exhibit the deletion of chromosome 17p13.1 (del[17p]). With a

Business Wire | July 29, 2021

Why BeiGene Stock Soared Today

A regulatory filing gave a sneak peek at the company''s second-quarter sales.

The Motley Fool | July 28, 2021

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 34% Undervaluation?

Does the July share price for BeiGene, Ltd. ( NASDAQ:BGNE ) reflect what it's really worth? Today, we will estimate the...

Yahoo | July 27, 2021

BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma

CAMBRIDGE, Mass. & BEIJING, July 26, 2021--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) has been approved by Health Canada for the treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy. This is the second approval for BRUKINSA in Canada,

Yahoo | July 26, 2021

Read More 'BGNE' Stories Here

BGNE Price Returns

1-mo 0.65%
3-mo 11.80%
6-mo -8.10%
1-year 54.04%
3-year 95.09%
5-year 1,207.74%
YTD 32.15%
2020 55.88%
2019 18.18%
2018 43.53%
2017 221.87%
2016 N/A

Continue Researching BGNE

Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:

BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0691 seconds.